TAVALISSE
Active substance: fostamatinib
TABLET · FOSTAMATINIB 100 mg/1
United StatesActive
Marketing holder: Rigel Pharmaceuticals, Inc.
Verified 2026-10-09 · openFDA NDC
- Source: openFDA NDC
- Countries with the substance registered: 1
Composition
- FOSTAMATINIB · 100 mg/1
Import and control
Control by country
- United Statesprescription only
Source: openFDA NDC · record 01a1208c-c1f8-76d0-b2f2-1e946a4caebf,01a1209e-4e04-7134-96c2-5484d4ceb3de;count=2 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- 71332-001
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- ORAL
Sources
- product · openFDA NDC · 71332-001 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 71332-001 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 71332-001 · Verified 2026-10-09 · open in source